increment color volum headwind continu
commentari dgx confer call suggest headwind vitamin
d/hcv/drug monitor improv still drag remaind
impact fy growth pama impact track expect
top price pressur lab industri typic face pleas see
recent industri primer howev manag note higher patient concess
result headwind may overshadow higher patient
deduct uninsur rate go forward intend improv patient revenu
collect collabor optum revenu cycl manag
initi outlook share gain sure slowli
indic anticip share gain expect happen
next sever year in-lin expect alreadi larg
unquantifi busi psc footprint area limit
see price compress volum switch in-network
contract open net posit revenu contributor next year pama price
overhang vs price
headwind plu side follow recent flurri deal
track sale growth upsid potenti hospit deal
addit headwind form hcv/vitamin d/pdm annual also target
patient servic center psc along psc
safeway see modest volum gain captur unfil requisit
adjust est better visibl trim po
updat guidanc model revenu
adj ep sale pull margin
unchang model revenu adj
ep trim po still base
adj ep estimate howev remain optimist opportun
reiter buy rate look lt guid updat dgx
investor day
net dbt
review messier hope
still pois share gain
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
largest provid clinic diagnost
test relat servic deliv
nation network full-servic clinic
laboratori patient servic center
clinic lab oper highli competit
price-deflationari environ howev
see upsid potenti elev lab
consolid catalyz medicar
opportun monet lab data
although trend may slow materi
believ quest scale customer-fac
mindset help compani leverag core lab
busi drive share gain margin
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
price object base price-to-earnings multipl line compani
averag two-year forward multipl last two year see upsid
potenti elev lab consolid catalyz medicar reimburs cut
pama retail clinic opportun monet lab data believ quest
scale customer-fac mindset help compani leverag core lab busi
drive share gain margin expans
upsid risk faster expect materi hospit lab consolid
trend margin expans due higher specialti test mix faster volum growth
consum genom trend
downsid risk greater expect price headwind lower expect test
volum growth competit execut risk integr risk data privaci risk
derik de bruin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
